Greffex has developed standardized, state-of-the-art processes that allow the manufacturing of our vaccines.
Short DNA segments are packaged into a protein delivery vehicle. They encode the production of one or several immunogens derived from a pathogen, and are devoid of any viral genes. The protein capsule efficiently delivers the genetic material to cells. The antigens are produced and immune responses are induced.
Greffex has developed standardized, state-of-the-art processes that allow the manufacturing of our vaccines. Our technologies exploit cell culture systems to assemble our products in a reproducible and scalable manner. Vaccines are purified by established chromatography methods.
By design, contaminations with helper viruses and replication competent recombinants are avoided. The ability to deliver large quantities of any GREVAX™ vaccine, via rapid and cost-effective means, is one of the crucial facets of the GREVAX™ Universal Platform technology. Greffex has developed manufacturing schemes that can ready millions of doses of vaccines for delivery within a few weeks, versus the multiple months required for competing technologies. Capital costs necessary to establish a vaccine manufacturing facility have been reduced by more than 90%.
Greffex has established a leading position in pandemic and bioterrorism vaccine delivery and is protecting this position with a comprehensive intellectual property portfolio.